Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Alnylam Partner Regeneron's CIDEBsiRNA Cuts Liver Fat by Up to 80% in Early Trial

By Public Technologies
  • Alnylam Pharmaceuticals announced first-in-human results showing its Regeneron-partnered CIDEBsiRNA rapidly normalized liver fat in patients with metabolic dysfunction-associated steatotic liver disease.
  • A single injection also improved liver injury markers, with effects sustained through 36 weeks in the ongoing Phase 1/2 trial.
  • Results were presented at AASLD's The Liver Meeting 2026 and published simultaneously in The New England Journal of Medicine.
  • Regeneron leads development and holds exclusive commercialization rights for the investigational treatment.
  • The partnership entitles Alnylam to development milestones and tiered, double-digit royalties up to 20%.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611101000BIZWIRE_USPR_____20261110_BW694883) on November 10, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.